In addition, we found that EMX2OS was significantly downregulated in the ccRCC validation set GSE167573 and TCGA_ccRCC (Figure 6D), which was also validated in clinical samples (Figure 6E). Here, EMX2OS is linked to nonpapillary renal cell carcinoma.